Synthesis of the Boc probe 3.
tert-butyl (3-(2-(2-(3-aminopropoxy) ethoxy)ethoxy)propyl)carbamate (11)
To a stirred solution of 9 (1.0 mL, 4.56 mmol) in CHCl 3 (100 mL) was added Boc 2 O (727 µL, 3.60 mmol) dripwise. After being stirred at room temperature for 20 min, the reaction was quenched with saturated aqueous NaHCO 3. The mixture was extracted with CHCl 3 , dried over anhydrous Na 2 SO 4 , and concentrated in vacuo. The mixture was chromatographed on a SiO 2 column with a stepwise elution of EtOAc, and CHCl 3 /MeOH (1/1). Fractions eluted with CHCl 3 /MeOH (1/1) were combined and concentrated in vacuo to afford 11 as a light yellow oil (523.2 mg, 45%): IR (neat) 3355, 2927, 2866, 1697, 1519, 1390, 1364, 1170, 1105, 861 cm -1 ; 1 H NMR (CDCl 3 , 500 MHz) δ 3.62-3.59 (br, 2H), 3.57-3.52 (ovl, 8H), 3.48 (t, J = 6.4 Hz, 2H), 3.10 (t, J = 6.9 Hz, 2H), 2.72 (t, J = 6.9 Hz, 2H), 1.71 (tt, J = 6.4, 6.4 Hz, 2H), 1.69 (tt, J = 6.4, 6.4 Hz, 78.8, 70.6, 70.3, 70.2, 69.6, 69.5, 39.6, 38.5, 33.2, 30.2, 29.7, 28.5 ; HRMS (ESI) -(3-(2,2-dimethyl-4-oxo-3,9,12,15-tetraoxa-5-azaoctadecan-18-yl)thioureido)-2-(6-hydroxy-3-oxo-3H-x anthen-9-yl) 
S4

Synthesis of probe 4.
4- ((18-(((3S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-((S)-6-methylheptan-2-yl)-2,3,4,7,8,9,10,11,12,1 3,14,15,16,17-tetradecahydro-1H-cyclopenta[a] phenanthren-3-yl)oxy)-15,18-dioxo-4,7,10-trioxa-14-azaoct adecyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid and 3,4,7,8,9,10,11,12,13,1 4,15,16,17-tetradecahydro-1H-cyclopenta[a] phenanthren-3-yl)oxy)-15,18-dioxo-4,7,10-trioxa-14-azaoctad ecyl)carbamoyl)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (4) Synthesis of compound 5. 2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(1-oxo-1-phenyl-6,9,12-trioxa-2-azapentadecan-15-yl 130.4, 129.6, 129.3, 128.3, 125.9, 120.0, 113.8, 111.6, 103.5, 71.5-71.0, 70.3, 70.3, 43.7, 38.7, 30.6, 30.4 
N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)benzamide (12)
N
Synthesis of compound 6.
(E)-2- (6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(1-oxo-1-phenyl-6,9,12-trioxa-2-azapentadecan-15-yl 
The thiourea compound 5 (7.6 mg, 0.0107 mmol), 0.2 mL of DMF/H 2 O (1/1), and 0.8 mL of n-propylamine (9.73 mmol, 909 eq) were mixed and stirred in a brown microtube at room temperature for 3 weeks. The reaction mixture was directly loaded on an ODS column, and chromatographed with a stepwise 
Synthesis of probe 8.
2, 2-dimethyl-4,20-dioxo-3,9,12,15-tetraoxa-5,19-diazatricosan-23-oic -4,20-dioxo-3,9,12,15-tetraoxa-5,19-diazatricosan-23-oate (14) 
2,5-dioxopyrrolidin-1-yl 2,2-dimethyl
N H O O O N H O O O O O N O O
S8
To a stirred solution of 13 (339.4 mg, 0.912 mmol) in CH 2 Cl 2 (20 mL) were added EDC . HCl (261.6 mg, 1.36 mmol) and DIEA (238.6 µL, 1.37 mmol). After being stirred at room temperature for 30 min, NHS (158.6 mg, 1.38 mmol) was added. After being stirred for 3 h, the reaction was quenched with 5% aqueous citric acid. The mixture was extracted with CHCl 3 . The organic layer was washed with saturated aqueous NaHCO 3 and brine, dried over Na 2 SO 4 , and concentrated in vacuo to afford 14 as a light brown oil (233.8 mg, 59%): IR (neat) 3327, 2929, 2870, 1814, 1784, 1737, 1697, 1660, 1529, 1365, 1170, 1070, 752 5, 169.9, 169.3, 168.3, 156.0, 78.7, 70.4, 70.1, 70.0, 69.6, 69.3, 38.3, 37.8, 30.3, 29.6, 28.9, 28.4, 26.7, 25.5 7-dioxo-12,15,18-trioxa-3,8-di Erythrocytes (10e8 cells/mL) were treated with N-ethylmaleimide (0.5 or 5 mM in 0.5% DMF) on ice and incubated at 37 ºC for 1 h with continuous mixing. After incubation, erythrocytes were washed with phosphate buffer (1 mL) twice, suspended in 1 mL of phosphate buffer, and treated with probe 2 or fluorescein-5-maleimide at 37 ºC for 8 h. 1 H NMR spectrum of 8 in CD 3 OD (500 MHz).
5-(3-(1-((((R)-2,3-bis(palmitoyloxy)propoxy)(hydroxy)phosphoryl)oxy)-4,
azahenicosan-21-yl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (8)
